ASH Annual Meeting 2018

Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019

By

Randi Hernandez

December 17, 2018

The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.

ASH Annual Meeting 2018

Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma

By

Lauren Burke

December 17, 2018

Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.

ASH Annual Meeting 2018

Postremission Survival Influenced by Choice of Induction Therapy in AML

By

Joyce Pagan

December 14, 2018

A single-center study demonstrated that induction therapy can influence OS and DFS in patients with intermediate or high NCCN risk acute myeloid leukemia.

Getting the results of a pregnancy test.

ASH Annual Meeting 2018

Conception, Pregnancy Possible During TKI Therapy for Chronic Myeloid Leukemia

By

Joyce Pagan

December 13, 2018

A retrospective and prospective study of Italian adult patients with CML investigated the potential for childbearing and outcomes in this patient population.

Fatigue is a common side effect of some cancer therapies.

ASH Annual Meeting 2018

Patients, Physicians Do Not Recognize Fatigue the Same

By

Joyce Pagan

December 10, 2018

A worldwide survey reveals that despite similar perceptions on symptom burden of ITP, patients and physicians do not agree on the effect of fatigue on quality of life.

ASH Annual Meeting 2018

PFS, OS Improved With Sequential Rituximab/Bendamustine, Rituximab/Cytarabine in Untreated Mantle Cell Lymphoma

By

Joyce Pagan

December 7, 2018

Two simultaneous studies demonstrate improved progression-free survival and overall survival in patients with uMCL who receive induction therapy with RB/RC followed by ASCT.